Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders

This article was originally published here

Under the strategic collaboration, the companies will develop and commercialise compounds in Takeda’s early-to-mid-stage psychiatry pipeline. As part of the deal, Neurocrine has secured an exclusive licence for

The post Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply